Friday, July 31, 2026

Coupang Under Fire: What Did CEO Harold Rogers Reveal in U.S. Congress?

Harold Rogers, interim CEO of Coupang Korea, testifies before the U.S. House on allegations of discriminatory treatment against the company.

Political Betting Trends: Why U.S. Users Dominated Polymarket with 570 Million USD in 2026

U.S. users placed $570M in political bets on Polymarket, focusing on geopolitical issues rather than elections, with notable interest in Ukraine.

How AI Is Set to Transform Your Internet Experience and End Outages

Experts believe that network outages might become a thing of the past with the advent of artificial intelligence (AI).

Tag: Zymfentra

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Celltrion’s Zymfentra Just Hit a New U.S. Prescription Record and the Growth Looks Serious

Celltrion's Zymfentra treatment saw a 185% surge in U.S. prescriptions, driven by effective marketing and reimbursement strategies.

How Celltrion’s Local Production Strategy Eliminates U.S. Drug Tariffs Influence

Celltrion resolves tariff impacts on U.S. sales, boosting local production and growth opportunities for its biosimilars, including Zymfentra.

How Zymfentra’s Prescription Rates Tripled in January: A Game-Changer for Celltrion

Celltrion's Zymfentra sees a 213% rise in U.S. prescriptions, marking significant growth since its launch, driven by market demand.

Celltrion’s Zymfentra: How This Breakthrough Drug is Driving Record Sales

Celltrion expects record sales driven by Zymfentra's success, expanding into new biosimilars and CDMO business for future growth.

K-Bio Targets the U.S. Market: Celltrion and Samsung Bioepis Close in on Originator Drugs

Celltrion and Samsung Bioepis are expanding in the U.S. market, showing strong growth in biosimilars like Zymfentra and Hadlima.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.